ATAI ATAI
Company Profile ↓Company Overview
ATAI (ATAI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 1227.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.09M (+1227.6% YoY); net profit $-660.05M.
- Trailing 12 Months Year-on-year growth — revenue +1227.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 1227.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1,227.60% |
| 1 Year: | 1,227.60% |
Stock Price Performance
| 1 Year: | +69.48% |
| 6 Months: | +86.56% |
| 3 Months: | +80.50% |
| 1 Month: | +39.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)74.29 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 1227.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 1.55M | 954.00K |
| Operating Income | -20.37M | -30.90M |
| Net Income | -26.43M | -29.78M |
| Diluted EPS | -0.15 | -0.08 |
| R&D Expense | - | 600.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 308.00K | 4.09M |
| Operating Income | -102.69M | -644.06M |
| Net Income | -149.27M | -660.05M |
| Diluted EPS | -0.93 | -2.91 |
| R&D Expense | 900.00K | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 159.39M | 292.72M |
| Total Equity | 116.30M | 221.87M |
| Cash & Equivalents | 17.50M | 85.30M |
| Long Term Debt | 14.13M | 0 |
| Total Liabilities | 42.83M | 70.72M |
| Current Liabilities | 24.95M | 23.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -82.44M | -102.67M |
| Investing Cash Flow | 59.17M | -109.13M |
| Financing Cash Flow | 5.37M | 269.48M |
| Capital Expenditure | -6.00K | -901.00K |
| Free Cash Flow | -82.44M | -103.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | -33,341.2% | -15,751.1% |
| Net Margin % | -48,464.0% | -16,142.0% |
| ROE % | -128.4% | -297.5% |
| ROCE % | -76.4% | -239.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATAI
Atai stock hits 52-week high at 7.22 USD - Investing.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPZEdHd3JzeUl4YjFoWmxlQTN1elNEUmNvMVV3ZU5IUWN0ZkRtX01ZQnB5UmthSHFyaWVMTW5Uc3pXbnpKdjVfTDVDdG9iUTFsREpJRUtkMVNaLUtWbUN0aW16bEJIblRhQWRtOE1ENWh5MTZRU01OWkJSNzV1TmJBY0U1dUtvX0FpU1VUSG…
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQNVQtS1hsQVJzTW1JQmVpWVFtbnJDaVkzeS03dTh5VFBHQ0lZOWZsZDc1TVA1Mi1NSjRxd2lMQ05Yb1VZTzZYY0ZOQmp6TWJWNl84dXVwRV9xUUdCNkZzbUR0WXc1aWlSRFpHN1JlbDNYbmdBU3Etb3RwU0ZuYk1pNEdYZkNwNFVYUUxhd2…
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders - TradingView
<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxOU1EzOHpxcmtiTVFwTUNCSWpaeGZCV3V6OVl4cFNOSTg5Wm1KbTZtd2RLZmhNSHQ1TXdmNWQ3SkJRQi1YWjE1SElTS0EwcGk3YmZkNWp0Rm90MkdXbTctUHhUcDQ2OW15bExlYmtmM19NMS1mYk1SYzlXUFp6Mk9ucnJoRnpQZHlZZWJPam…
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWHQxenNBSy02MzZSdVB3S2w5SVRMb2oyX2NFdjNJakJfYndHOXhaTm04cG5ldWNrY0NuX3JiaWJQMllIbE0ySWdrVnlNY3ppcU1tc0pjM3FXb0RaV1pscmdraVFTX1Y1LThQVFdPeE9saEJvSmRTT3BVaTdOTHI1OGxZSE5FY3NaX2tCUm…
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPWVA5S0ZmbVhzc0w3UkFDUUNIbUtEYUdWVDJiNFZZRTI5YS1XRDdtVmE4bXU2ZGVJYjlieGJWdF9TS0N0QUlUUkxiMDRmVllNTGVDbEltMDlodFdUaHBmcWdPdjlIdmVvTFNmMlNLRlctc1BtcVdIdFU4LUViNFRaY0NJdU9BQlVkdktrdH…
AtaiBeckley Inc. (ATAI) Stock Analysis: Navigating Challenges with a Potential 33.53% Upside - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNMV94aDRVZHU5dGFFeGt4ZmZnNF9Wa0VoRGJDVW9XQjdIMnpZbTg4VjFkQlFYQjZhekJPMXUzOGR0WXlwUy1NMFRtU0QxR0NvR1NsUWRaOFN0a1c0Y3A3eUtEdEVJdUlKQjVpX1VGQmVzYThuRzJHYUJ5YmcwbUFPbEdLUVdnUnNSdnRMRz…
ATAI — Frequently Asked Questions
What is the current share price of ATAI?
As of 2026-08-05 17:25 PDT, ATAI trades at $7.22 on NASDAQ/NYSE. Its 52-week range is $3.35 to $7.22.
What is the P/E ratio of ATAI?
ATAI trades at a trailing price-to-earnings (P/E) ratio of -2.48.
Is ATAI a good stock to buy?
This page provides a data-driven analysis of ATAI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.